CINCINNATI, OH (FOX19) - Cincinnati Children's Hospital Medical Center has received a $12 million grant from the National Institutes of Health to conduct the first clinical trial to determine the medication of choice for preventing migraines in children and teens.
According to hospital officials, migraines affect more than six million children and adolescents in the United States, with an annual economic impact of $36 billion. There is no FDA-approved medication to prevent childhood migraines and there are no evidence-based studies.
The five-year study, to be conducted at up to 40 sites throughout the United States, will be led by Andrew Hershey, MD, PhD, and Scott Powers, PhD, who co-direct the Headache Center at Cincinnati Children's, which will serve as the clinical coordinating center.
The University of Iowa has received a $5.8 million grant to serve as the data coordinating center for the study.
"Children and teens miss more than 130,000 school days every two weeks due to migraines," says Dr. Hershey.
"The negative impact of having migraines on overall quality of life is similar to childhood cancer, heart disease and rheumatic disease," adds Dr. Powers.
The study is intended to:
- determine which drug is superior for reducing migraine frequency and disability
- estimate how well each drug is tolerated
- determine the "safety profiles" of each therapy